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Purpose: Pseudoaneurysm is a known complication of arteriovenous grafts in chronic hemodialysis and can result in graft
disruption or thrombosis if left untreated. This study evaluated the safety and efficacy of endovascular repair with
Wallgraft endoprosthesis (Boston Scientific, Inc, Watertown, Mass) in a porcine arteriovenous graft (AVG) pseudoan-
eurysm model.
Materials and Methods: Bilateral groin AVG pseudoaneurysms (n  18) were created with an oversized Dacron
interposition graft within a polytetrafluoroethylene femoral AVG in nine domestic swine and allowed to mature 28  4
days (standard deviation). Transluminal placement of Wallgraft was performed to exclude the pseudoaneurysm from the
AVG circulation. Hemodialysis was performed (400 mL/min  1 hour, with intravenous heparin 30 units/kg) every 4
days for a total of 6 weeks via 15-gauge needles in the treated AVG pseudoaneurysm site. Arteriography and duplex
ultrasound scan were performed to determine AVG patency and pseudoaneurysm flow. Histologic evaluation was
performed to determine Wallgraft morphology. In vitro pulsatile flow chamber was used to determine maximal flow
volume without peri-Wallgraft endoleak.
Results: All AVG pseudoaneurysms were successfully excluded with the Wallgrafts. Twelve AVG (67%) remained patent
at the completion of the study. No Wallgraft migration occurred from hemodialysis. Transient peri-Wallgraft endoleak
(<2 hours after hemodialysis) was present in 13 of 18 (72%) and four of 12 (33%) AVG pseudoaneurysms by weeks 1 and
6, respectively. With maintenance of an intraluminal pressure of 80, 100, 120, 140, and 160 mm Hg in the pulsatile flow
chamber, the maximal flow rates without peri-Wallgraft endoleak were 625  120, 650  145, 620  95, 425  110,
and 262 86 mL/min. Scanning electron microscopy showed a neointimal layer covered with thrombus on the Wallgraft
surface.
Conclusion: Endoluminal placement of Wallgraft endoprosthesis provides adequate structural support for continuous
hemodialysis after AVG pseudoaneurysm exclusion. Transient blood flow in the pseudoaneurysm cavity may occur
immediately after the hemodialysis, which may represent the effect of heparin used during hemodialysis. This study
suggests Wallgraft is a safe and effective treatment for AVG pseudoaneurysm and permits continuous hemodialysis. (J
Vasc Surg 2003;37:175-81.)
The prevalence of end-stage renal disease (ESRD) and
the number of patients who need maintenance hemodialy-
sis have risen steadily over the past two decades. According
to the 1999 Annual Report of the United States Renal Data
System, more than 300,000 patients with ESRD in the
United States undergo maintenance hemodialysis annual-
ly.1 Surgical procedures for hemodialysis access have be-
come the most common vascular operation in this country
today. The leading causes of morbidity in the ESRD patient
population are related to both vascular access placement
and the resultant complications associated with the pros-
thetic arteriovenous graft (AVG).2
Several complications are associated with prosthetic
AVG placement and include graft thrombosis, infection,
and pseudoaneurysm formation. The development of an
AVG pseudoaneurysm is in part from the repetitive punc-
ture during the hemodialysis sessions at the same graft
location that resulted in thinning of the prosthetic graft
material. With chronic hemodialysis, the weakening of the
prosthetic graft fabric ultimately leads to the pseudoaneu-
rysm formation. Moreover, pseudoaneurysm can also occur
from poor puncture technique of the AVG before it is fully
matured. Traditional treatment of choice for an AVG pseu-
doaneurysm is resection or ligation of the AVG pseudoan-
eurysm followed by interposition graft placement. Often
despite a successful surgical repair, the newly placed inter-
position AVG may require a period of 3 or 4 weeks before
it is matured for dialysis access. Furthermore, with these
surgical revision procedures, available access sites in the
upper extremities will become scarce. Use of alternative
strategies to maintain continuous hemodialysis access in the
treated AVG pseudoaneurysms becomes important.
We recently reported our clinical experience of use of a
covered stent graft in the treatment of AVG pseudoaneu-
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rysms as a means to exclude the pseudoaneurysm from the
AVG circulation.3 Our study showed percutaneous covered
stent graft placement can be performed to treat AVG
pseudoaneurysm while permitting immediate hemodialy-
sis. One advantage of a covered endograft to treat AVG
pseudoaneurysms is that it permits continuous hemodialy-
sis immediately after the endovascular treatment. Our study
showed that stent graft placement to exclude AVG pseudo-
aneurysm is safe and feasible with similar short-term pa-
tency when compared with the traditional surgically treated
AVG pseudoaneurysms.3
In this study, we examined the structural integrity of
the Wallgraft endoprosthesis (Boston Scientific, Inc, Wa-
tertown, Mass) after hemodialysis in an AVG pseudoaneu-
rysm model with duplex scanning to assess peri-Wallgraft
endoleak. In addition, we examined the structural integrity
of the Wallgraft with a hemodynamic flow circuitry after
chronic hemodialysis to assess peri-Wallgraft endoleak. The
AVG pseudoaneurysm model incorporates an oversized
Dacron graft (Boston Scientific, Natick, Mass) within a
polytetrafluoroethylene femoral vessel loop AVG. The aim
of this study was to assess the effect of chronic hemodynam-
ics of a stent graft in an experimental AVG pseudoaneurysm
model. The structural integrity of the stent graft was exam-
ined after hemodialysis. In addition, a pulsatile flow cir-
cuitry was used to determine the maximum flow in the
Wallgraft after chronic hemodialysis without peri-Wallgraft
endoleak.
MATERIALS AND METHODS
Animal model. Nine adult domestic swine, each
weighing 45 to 50 kg, were used in this study. All animal
procedures and care were performed in accordance with the
Guideline for the Care and Use of Laboratory Animals
(NIH publication no. 80-23, revised 1985). All experimen-
tal procedures were conducted with the US Food and Drug
Administration’s Good Laboratory Practice for Non-clini-
cal Laboratory Studies Regulations (21 CFR, Part 58).
Prophylactic cefazolin (1 g, Kefzol, Marsam Pharmaceuti-
cals, Cherry Hill, NJ) was administered intramuscularly.
Animals were given thiopental sodium (10 mg/kg intrave-
nously, Pentothal, Abbott Laboratories, North Chicago,
Ill). Endotracheal intubation was performed, and anesthe-
sia was maintained with 1% isoflurane (Rhone-Poulenc,
Bristol, United Kingdom). With sterile conditions, bilateral
oblique incisions were made 2 cm below the inguinal
ligament, whereby both common femoral arteries and veins
were exposed. All animals were given intravenous heparin
before vessel clamping (50 units/kg intravenous bolus).
With a 6-mm straight expanded polytetrafluoroethylene
graft (Gore-Tex, WL Gore, Flagstaff, Ariz), a 30-cm loop
arteriovenous shunt was created in the subcutaneous space
with end-to-side anastomoses with use of 6-0 polytetra-
fluoroethylene suture (Gore-Tex). A 4-cm segment of
oversized interposition Dacron graft 12 mm in diameter
was placed in the middle portion of the polytetrafluoroeth-
ylene graft to create an AVG pseudoaneurysm. Completion
angiogram was performed to ensure the patency of AVG
pseudoaneurysm and the anastomotic patency (Fig 1). The
groin wounds were closed in layers with 3-0 Dexon suture
(Davis-Geck, Manati, Puerto Rico). Each animal was given
500 mg cefadroxil (Ceftabs, Fort Dodge Laboratories, Fort
Dodge, Iowa) orally daily for 5 days. The AVGs were
examined daily with palpation and auscultation to assess
graft patency.
Wallgraft endoprosthesis. The endoluminal device
used in our study was the Wallgraft endoprosthesis, which
is a self-expanding stent graft that consists of a braided
multifilament textured yarn polyethylene terephthalate
(PET) graft on the outside covering a flexible braided
Elgiloy stent. The stent is coated with Corethane adhesive
(Boston Scientific), which bonds the graft throughout its
entire length. The device tracts over a 0.035-in guidewire.
The deployment process involves first inserting the device
into an introducer sheath placed in the AVG, followed by
withdrawing the outer constraining jacket, thus allowing
expansion of the device. All devices used in this study were
8 mm in diameter and 7 cm in length. These devices
required a 9F introducer sheath for deployment.
Wallgraft exclusion of the AVG pseudoaneurysm.
Four weeks after the AVG pseudoaneurysm creation, ani-
mals were given general anesthesia with endotracheal intu-
bation. The Wallgraft was placed in each AVG pseudoan-
eurysm to exclude it from the AVG circulation. This was
achieved by cannulating the AVG percutaneously 6 cm
away from the pseudoaneurysm with a single wall puncture
needle (Cook, Inc, Bloomington, Ind). A 0.035-in Bent-
son wire (Cook) and a 9F introducer sheath (Boston Sci-
entific) were placed in the AVG. The Wallgraft was next
inserted over the guidewire through the introducer sheath
Fig 1. Experimental AVG pseudoaneurysm model used in our
study is created with 6-mm polytetrafluoroethylene graft in femo-
ral arteriovenous circulation with interposing 12-mm Dacron graft
in middle, which created overdilated pseudoaneurysm segment
shown on arteriogram.
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and deployed to exclude the pseudoaneurysm with proxi-
mal and distal landing zones in the polytetrafluoroethylene
grafts. Completion angiogram was performed to ensure the
pseudoaneurysm exclusion. The guidewire and introducer
sheath were removed from the skin.
Hemodialysis and follow-up study. One week after
the Wallgraft placement, hemodialysis was performed on
each animal every 4 days for a total of 6 weeks. Hemodial-
ysis was performed by cannulating the AVG pseudoaneu-
rysm through the Wallgraft with two 15-gauge needles that
were connected to a hemodialysis system (Baxter Corp,
Deerfield, Ill) at 400 mL/min for 1 hour (Fig 2). A total of
10 hemodialysis sessions were performed in each AVG,
which endured at least 20 needle punctures for hemodial-
ysis during the study period. Each animal also received
systemic heparin of 30 units/kg during hemodialysis. Pres-
ence of peri-Wallgraft endoleak after hemodialysis was as-
sessed with both arteriography and duplex imaging scan-
ning (Apogee 800, Advanced Technology Laboratories,
Ambler, Pa).
Histology and electron microscopy. Segments of
one Wallgraft from each animal were excised for histologic
and scanning electron microscopic (SEM) evaluation. Har-
vested specimens included at least 3 cm of the Wallgraft
that was fixed in 10% buffered formalin overnight and then
transferred to 70% alcohol. The specimens were dehydrated
with sequentially increasing concentrations of ethanol fol-
lowed by xylene and embedded in paraffin. Five-microme-
ter cross sections were cut and prepared as previously
described.4,5 Sections were cut with a diamond-coated
band saw (EXAKT System, EXAKT Technologies, Okla-
homa City, Okla). Each segment was embedded in methyl
methacrylate and sectioned to a thickness of 40 m. His-
tologic stainings with hematoxylin and eosin and methyl-
ene blue were performed.
For SEM, the Wallgraft specimen was incised to allow
en face imaging. This tissue specimen was placed in 2%
glutaraldehyde and fixed overnight. The specimens were
rinsed in phosphate-buffered saline solution three times
and then dehydrated in a graded series of ethanol (30% to
100%). The tissue samples were placed with a graded series
of hexamethyldisilazane, air dried, and gold sputter coated
before imaging (Cambridge 360 SEM microscope, Ox-
ford, UK). The luminal surface of the Wallgraft on the basis
of the SEM image was scanned and evaluated by a blind
observer with a computer image software (Bioview Image,
Atlanta, Ga). A subjective scale of structural damage was
scored (0, none; 1, minimal; 2, mild; 3, moderate; and 4,
severe).
Flow chamber analysis. The contralateral AVG was
harvested in its entirety, incorporating the Wallgraft-ex-
cluded pseudoaneurysm. The AVG was connected to an in
vitro fluid circuit system (Fig 3). The perfusion fluid was a
solution of a 44% glycerin diluting with distilled water to
formulate the similar viscosity and specific gravity of blood.
The proximal and distal ends of the AVG were inserted into
acrylic pipes with an internal diameter of 10 mm. Both ends
were glued with cyanocrylate and fixed with sealed straps at
the proximal and distal ends of the AVG. The proximal
tube was connected to a tap water source, and the distal
tube was connected to a Harvard cardiovascular pump
(Harvard Apparatus, Holliston, Mass) to create pulsatile
pressure. The pump was set at 72 bpm with a stroke volume
of 30 mL. These parameters were kept constant through-
out all experiments. A 5F Berenstein catheter (Boston
Scientific) connected to a transducer was also attached to
the distal tube via a Y-adapter and placed within the Wall-
graft for pressure monitoring. A second 5F Berenstein
catheter (Boston Scientific) connected to a pressure trans-
ducer was used to cannulate the pseudoaneurysm to deter-
mine the presence of peri-Wallgraft endoleak as evidenced
with flow pulsatility. The luminal pressure was monitored
with a multichannel recorder (TMS1000, Biotronic Corp,
Toronto, Canada). For flow measurements, an extracorpo-
real electromagnetic flow transducer was used (Biomedicus
Transducer model TX40, Medtronic, Minneapolis, Minn).
Pulsatile flow with varying mean pressures (range, 80 to
160 mm Hg) was created to determine the maximal flow
volume without peri-Wallgraft endoleak.
Statistical analysis. The presence of peri-Wallgraft
endoleak after each dialysis was assessed with duplex ultra-
sound scan. The maximal flow volume without peri-Wall-
graft endoleak was assessed with the in vitro flow chamber.
All values were expressed as mean  standard error of
mean. The peri-Wallgraft endoleak at different time points
was analyzed with one-way analysis of variance or Student t
test where appropriate. An SAS statistical package was used
for analysis (version 5.0, Abacus Concepts, Berkeley, Calif).
Significance was considered when the P value was less than
.05.
Fig 2. Four weeks after AVG creation, Wallgraft was inserted to
exclude AVG pseudoaneurysm. Hemodialysis was perforemd with
puncture of Wallgraft with two 15-gauge needles to maintain flow
rate of 400 mL/min for 1 hour. Hemodialysis was performed in
each animal every 4 days for a total of 6 weeks.
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RESULTS
Implant. All AVG pseudoaneurysms were success-
fully excluded with the Wallgraft. One animal died 3 weeks
after the AVG implantation procedure, and another animal
had bilateral groin infection develop 3 weeks after the
initiation of the hemodialysis. These animals were excluded
from the analysis. Two additional AVGs in two animals
(2/14; 15%) were thrombosed before the 6-week matura-
tion period. Therefore, 12 AVGs (67%) remained patent at
the completion of the study. Hemodialysis was performed
successfully with cannulating the Wallgraft in all sessions.
Color flow duplex scanning was performed within 2 hours
after each hemodialysis session. The incidence rates of
peri-Wallgraft endoleak immediately after hemodialysis at
1, 2, 3, 4, 5, and 6 weeks were 72%, 62%, 54%, 50%, 33%,
and 33%, respectively. Arteriogram showed similar inci-
dence rates of endoleak immediately after hemodialysis,
which were 72%, 64%, 50%, 33%, and 33% at 1, 2, 3, 4, 5,
and 6 weeks, respectively. No evidence of peri-Wallgraft
endoleak was found when duplex scanning was performed
24 hours after each hemodialysis session. No bleeding
complication occurred as the result of hemodialysis needle
cannulation. Conversely, no Wallgraft migration occurred
as the result of the hemodialysis.
Flow chamber analysis. The explanted Wallgraft was
connected to the in vitro flow chamber to determine the
maximal possible flow rate without causing peri-Wallgraft
endoleak. When maintaining an intraluminal pressure of
80, 100, and 120 mm Hg in the pulsatile flow circuitry, the
maximal flow rates without peri-Wallgraft endoleak were
625  120, 650  145, and 620  95 mL/min (Fig 4).
However, when the intraluminal pressure was increased
above 120 mm Hg, the maximal flow rate had to be
reduced incrementally to maintain an absence of peri-
Wallgraft endoleak. Consequently, as the pressure was in-
creased to 140 and 160 mm Hg, the maximal flow rates
without peri-Wallgraft endoleak were decreased 425 110
(P  .05) and 262  86 mL/min (P  .02), respectively.
Histology and electron microscopy. Segmental
thrombus was visible grossly in eight explanted Wallgrafts
at 6 weeks (66%). These thrombi were also visible in
arteriography after the hemodialysis. Light microscopy re-
vealed a thin layer of neointimal lining throughout the
entire length of the 10 Wallgrafts (10/12; 83%). Varying
degrees of endothelial cells were adherent to the Wallgraft
surface within the neointimal lining. At 6 weeks, these
neointimal layers consisted of irregular fibrous matrix with
loosely packed smooth muscle cells. SEM revealed a thin
neointimal layer consisting of thrombus and scattered
platelet and red blood cell deposition (Fig 5). Factor VIII
or immunohistologic stains to test for the presence of
functional endothelium were performed. A thin layer of
fibrous tissue was also present between the Wallgraft and
the Dacron prosthetic graft. The PET fibers in the mid
section of the Wallgraft revealed a less pronounced inflam-
matory reaction than at the ends of the prosthesis. Along
the entire length of the Wallgraft were large irregular holes
created by the hemodialysis needles. These irregular holes
were associated with patchy thrombus and platelet aggre-
gates. The mean structural damage score was 2.2  0.3.
DISCUSSION
Pseudoaneurysm formation is a well-known complica-
tion after AVG or fistula creation, and the incidence rates
ranged between 2% and 10%.6-8 The traditional treatment
approach is surgical excision or ligation of the pseudoaneu-
rysm followed by interposition grafting with a prosthetic
conduit. The possibility of treating an AVG pseudoaneu-
rysm with a stent graft device for pseudoaneurysm exclu-
sion provides a less invasive treatment alternative along
Fig 3. In vitro fluid circuitry. A, Flow-regulated faucet provides inflow water source; B, AVG pseudoaneurysm, which
has been excluded with Wallgraft; C, 5F catheter measures pressure within Wallgraft fluid circuitry; D, another 5F
catheter measures peri-Wallgraft endoleak, or flow within pseudoaneurysm; E, double-channeled pressure transducer
monitor records pressures from both Wallgraft and pseudoaneurysm; and F, roller pump provides pulsatile pressure
within fluid circuit.
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with several advantages. First, it permits continuous hemo-
dialysis access of the AVG without the need of temporary
dialysis catheter placement. Second, no surgical incision is
necessary for stent graft placement, which may be associ-
ated with decreased blood loss. Lastly, it preserves the
patency of the same AVG for continuous hemodialysis
without the need for searching for potential sites for a new
AVG placement.
The application of stent graft devices in the manage-
ment of AVG-related complications is not a novel concept.
However, its application has been largely limited to the
management of venous anastomotic stenosis or occlusion.
Other studies have shown that stent graft device is benefi-
cial in the treatment of venous outflow stenosis by provid-
ing a scaffold to maintain the outflow patency.9,10 Re-
searchers also postulated that the stent graft may provide a
theoretic advantage of reducing restenosis by excluding the
anastomotic stenosis from direct contact with the proco-
agulant elements in the circulation. Several studies have
similarly reported various endovascular strategies for AVG
pseudoaneurysms. Selby and colleagues11 described percu-
taneous placement of a detachable balloon to induce pseu-
doaneurysm thrombosis but with varying degrees of suc-
cess. Others have created a home-made stent graft device
with the Palmaz stent and polytetrafluoroethylene graft to
exclude AVG pseudoaneurysm. Such a treatment strategy
has not been widely embraced because of the risk of crush-
ing the balloon-expandable stent from external arm com-
pression.12-14 Hausegger and colleagues15 reported their
experience with Cragg Endo-Pro stent grafts (Boston Sci-
Fig 4. Flow-pressure curve shows maximal pulsatile flow within in vitro flow circuitry without peri-Wallgraft endoleak
(PWE).
Fig 5. SEM of luminal surface of explanted Wallgraft revealed thin neointimal layer consisting of thrombus and
scattered platelet (white arrow) and red blood cell deposition (black arrow).
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entific) to exclude AVG pseudoaneurysms and noted the
repeat puncture of the stent graft may lead to delayed
pseudoaneurysm recurrence from degenerative breakdown
of the graft materials. We recently reported our early expe-
rience with the Wallgraft in 10 patients in the management
of AVG pseudoaneurysm and found continuous hemodial-
ysis is possible after Wallgraft insertion in AVG pseudoan-
eurysms.3 In that study, all patients were able to resume
hemodialysis in the Wallgraft-treated AVG site within 48
hours, and postoperative duplex scan showed successful
exclusion in AVG pseudoaneurysms without endoleak. In
this study, we examined the structural integrity of Wallgraft
after hemodialysis in an AVG pseudoaneurysm model with
duplex scanning to assess peri-Wallgraft endoleak. In addi-
tion, we examined the structural integrity of the Wallgraft
with a hemodynamic flow circuitry after chronic hemodial-
ysis to assess peri-Wallgraft endoleak.
Transient peri-Wallgraft endoleak occurred after each
dialysis session when examined with color duplex scanning.
The prevalence of the peri-Wallgraft endoleak decreases
with time. Because intravenous heparin was given systemi-
cally in all animals, we postulated that the flow within the
pseudoaneurysm was in part from the anticoagulation and
flow circulation through the dialysis needle tracks across the
Wallgraft. This is supported by the fact that the peri-
Wallgraft endoleak was not detectable with the color du-
plex scan 24 hours after the hemodialysis. The Wallgraft
endoprosthesis was durable to withstand the hemodialysis
at the flow rate of 400 mL/min in the in vivo animal model.
During the in vitro pulsatile flow chamber analysis, the
explanted Wallgraft could withstand a flow rate of 600
mL/min or greater without detectable peri-Wallgraft en-
doleak when the pressure was kept at less than 120 mm Hg.
When the intraluminal pressure was sequentially increased
to more than 120 mm Hg, it created greater flow shear
stress that rendered potential leakage across the punctured
Wallgraft. As the result, the maximal flow rate without
peri-Wallgraft endoleak decreased accordingly.
The biologic properties of a graft material in an endolu-
minal device have received wide investigative focus, partic-
ularly with regards to thrombogenicity and tissue reaction
after in vivo implantation. The Wallgraft is composed of
PET graft material and a braided Elgiloy stent. Researchers
have reported comparable tissue reactions regarding both
PET and polytetrafluoroethylene prostheses.16,17 In our
study, a neointimal layer consisting of thin mural thrombus
was present within the PET surface of the Wallgraft, which
was eventually organized into a fibrotic layer with cellular
covering. Other researchers have reported similar findings
of luminal endothelialization after stent graft placement in
animal models.18,19 Hussain and colleagues19 evaluated
the histologic reaction of Wallgraft after implantation in
canine aorta and reported that PET grafts readily incorpo-
rated with the fibrous tissue, which subsequently developed
luminal endothelialization at 2 weeks. The PET graft ma-
terial in the Wallgraft has similar tissue reaction and healing
characteristics compared with the conventional polyester
prosthetic graft.20,21
The biologic properties of a graft material in an endolu-
minal device may impact on the performance of its clinical
application. For instance, researchers have suggested that
surface materials in the endoluminal graft with increased
thrombogenicity may be an advantage when used in the
case of aneurysm or pseudoaneurysm exclusion because
they may potentiate thrombosis of the stagnant blood flow
in the excluded pseudoaneurysm lumen.22 In a study that
compared the tissue response between woven polyester and
polytetrafluoroethylene stent graft, the researcher noted
that polyester material induced a greater degree of inflam-
matory tissue reaction and intimal hyperplasia.23-25 Al-
though such a biologic property may not necessarily be a
desirable feature in treatment of an anastomotic stenosis,
we speculate that its induction of intimal hyperplasia and
inflammatory reaction may be helpful for long-term stabil-
ity of the stent graft after pseudoaneurysm exclusion be-
cause it accelerates adhesion of the stent graft to the pseu-
doaneurysm wall.
We found that the placement of Wallgraft to exclude
the AVG pseudoaneurysm in our model was technically
feasible without subsequent risk of migration. This was
likely in part from the adequate proximal and distal landing
zone created by the polytetrafluoroethylene graft in our
AVG model. In our study, we placed an 8 mm-diameter
Wallgraft within the 6-mm polytetrafluoroethylene AVG,
which created a 33% oversize in the stent graft diameter,
which provided a secure fixation of the Wallgraft within the
prosthetic polytetrafluoroethylene graft. The Wallgraft has
a relatively low profile and maintains adequate support of
the PET graft. These characteristics reduce the risk of
kinking the polyester fabric or of compression from the
external forces. The Wallgraft also conforms well to the
vessel wall curvature after deployment. Balloon angioplasty
of the Wallgraft to assure fixation to the AVG did not
produce visible enlargement in the device diameter, sug-
gesting that the Wallgraft fully expanded immediately after
its deployment. Structural analysis of our study showed that
continuous hemodialysis can be performed after Wallgraft
placement without fabric disintegration with the repeated
hemodialysis or the needle puncture.
In conclusion, our study showed that endoluminal
placement of the Wallgraft is effective in excluding an AVG
pseudoaneurysm in our experimental model and permitted
repeated needle puncture for continuous hemodialysis.
Our study supports further clinical evaluations for this
device in the treatment of pseudoaneurysm exclusion.
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